Health Care • Biotechnology: Pharmaceutical Preparations
$59.95 ▼ -1.23
(-2.01%)
MKT CAP: $9.36B • VOL: 2.58M
52W L $27 52W H $62
TGTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $616.3M | $329.0M | $233.7M |
| YoY Revenue Growth % | +87.3% | +40.8% | — |
| Gross Profit | $515.6M | $290.5M | — |
| Gross Margin % | 83.7% | 88.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $123.3M | $41.9M | $20.6M |
| Operating Margin % | 20.0% | 12.7% | 8.8% |
| Net Income (GAAP) | $447.2M | $23.4M | $12.7M |
| EBITDA (Normalized) | $123.5M | $42.0M | $29.0M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$24.8M | -$40.5M | -$31.4M |
| Capital Expenditures (CapEx) | $214.0K | $45.0K | $10.5M |
| Free Cash Flow (FCF) | -$25.0M | -$40.6M | -$41.9M |
| FCF Margin % | -4.1% | -12.3% | -17.9% |
| Return on Invested Capital (ROIC %) | 12.0% | 11.5% | 0.6% |
| Cash & Short-Term Equivalents | $79.1M | $179.9M | — |
| Total Debt (Short + Long Term) | $245.6M | $244.4M | $1.14B |
| Total Stockholders' Equity | $648.0M | $222.4M | $2.35B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TGTX.